Stockreport

4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation

4D Molecular Therapeutics, Inc.  (FDMT) 
PDF Cystic Fibrosis Foundation to provide up to $11 million in additional funding to accelerate development of 4D-710 for cystic fibrosis, following program and clinical dat [Read more]